Humana faces severe headwinds from rising medical costs and a dramatic drop in 4-STAR Medicare Advantage membership, pressuring margins and profitability. Learn more about HUM stock here.

On February 25, Barclays lowered its price recommendation on Humana Inc. (NYSE:HUM) to $176 from $245. The firm reiterated an Equal Weight rating on the shares.

The kid who learns to run conduit and terminate high-voltage panels in a well-funded high school program may ultimately have a clearer path to financial security than many of their college-bound ...

Among the almost constant noise surrounding the Tennessee Titans franchise this offseason has been a low, rumored hum regarding a supposed impending rebrand. Th ...

Stock index futures rose sharply on Wednesday as traders assessed January’s nonfarm payroll report. Here are four stocks to watch on the day: Shopify (SHOP) shares rallied 11.3% in premarket trading ...

Health insurance company Humana (NYSE:HUM) will be reporting results this Wednesday before market hours. Here’s what to look for. Humana beat analysts’ revenue expectations by 2.1% last quarter, ...

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. If you are wondering whether Humana's current share price really reflects what ...